Non-response to first-line anti-tuberculosis treatment in Sikkim, India: a risk-factor analysis study

This article aims to assess the factors associated with non-response to treatment

Abstract

Sikkim, India, has the highest proportion of tuberculosis (TB) patients on first-line anti-tuberculosis regimens with the outcome ‘failure’ or ‘shifted to regimen for multidrug-resistant TB (MDR-TB)’. This article aims to assess the factors associated with non-response to treatment, i.e., ‘failure’ or ‘shifted to MDR-TB regimen’.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Singhi L, Sagili KD, Sharath BN, Bhandari K, Dadul PK, Gautam M, Ravichandra C, Chadha S, Satyanarayana S. Non-response to first-line anti-tuberculosis treatment in Sikkim, India: a risk-factor analysis study. Public Health Action. 2018 Dec 21;8(4):162–8.

Non-response to first-line anti-tuberculosis treatment in Sikkim, India: a risk-factor analysis study

Updates to this page

Published 21 December 2018